Personalized approach to the treatment of patients with skin psoriasis and inflammatory back pain, taking into account comorbid pathology

封面

如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Backrground. In psoriasis (PS), a complex immune cascade with the participation of both the innate and adaptive immune systems occurs, and is characterized by the development of multiple comorbid pathologies that complicate the course of the underlying disease.

Objective. Evaluation of the safety profile and effectiveness of genetically engineered biological drugs from the group of IL-17A inhibitors (netakimab) in patients with smooth skin PS and inflammatory back pain, taking into account comorbid pathologies.

Methods. 39 patients with PS were followed-up: 21 (53.8%) men and 18 (46.2%) women aged 18–48 years (mean age 35.3±2.1 years), who received the genetic therapy netakimab at a dosage of 120 mg subcutaneously at weeks 0, 1, 2 and then 120 mg every month for 52 weeks.

Results. The majority of patients taking netakimab noted significant positive changes in the skin and joints by the end of the 3rd week of therapy. By week 12, 36 (92.3%) patients achieved PASI 75, 33 (84.6%) – PASI 90 and 31 (79.5%) patients – PASI 100. By week 24, delta PASI 75 was noted in 38 (97.4%) patients, PASI 90 – in 37 (94.9%) patients, PASI 100 – in 35 (89.7%) patients. By week 52, 39 (100%) patients achieved PASI 75, 39 (100%) achieved PASI 90, and 38 (97.4%) patients achieved PASI 100.

Conclusion. IL17-A inhibitors (netakimab) have shown high efficacy and a favorable safety profile against the clinical symptoms of PS, inflammatory back pain (possibly as early signs of psoriatic arthritis) and multiple concomitant comorbid pathologies.

全文:

受限制的访问

作者简介

N. Pereverzina

Central State Medical Academy of the Presidential Administration of the Russian Federation; National Medical Research Center of Otorhinolaryngology FMBA

编辑信件的主要联系方式.
Email: natalia.pereverzina@gmail.com

Cand. Sci. (Med.)

俄罗斯联邦, Moscow; Moscow

L. Kruglova

Central State Medical Academy of the Presidential Administration of the Russian Federation

Email: kruglovals@mail.ru
俄罗斯联邦, Moscow

参考

  1. Reich K. The concept of psoriasis as a systemic inflammation: implications for disease management. J Eur Acad Dermatol Venereol. 2012;26(Suppl. 2):3–11. doi: 10.1111/j.1468-3083.2011. 04410.x.
  2. Ryan C., Kirby B. Psoriasis is a systemic disease with multiple cardiovascular and metabolic comorbidities. Dermatol Clin. 2015;33(1): 41–55.
  3. Донцова Е.В., Олисова О.Ю., Круглова Л.С. Псориаз и метаболический синдром: механизмы коморбидности. Медицинский алфавит. Дерматология. 2019;7(382)1:34–9. [Dontsova E.V., Olisova O.Yu., Kruglova L.S. Psoriasis and metabolic syndrome: mechanisms of comorbidity. Medical alphabet. Dermatology. 2019;7(382)1:34–9. (In Russ.)].
  4. Owczarczyk-Saczonek A., Placek W. Interleukin-17 as a factor linking the pathogenesis of psoriasis with metabolic disorders. Int J Dermatol. 2017;56:260–68.
  5. Oliveira M. de F., Rocha B. de O., Duarte G.V. Psoriasis: Classical and emerging comorbidities. An Bras Dermatol. 2015;90(1):9–20. doi: 10.1590/abd1806-4841.20153038.
  6. Kremers H.M., McEvoy M.T., Dann F.J., Gabriel S.E. Heart disease in psoriasis. J Am Acad Dermatol. 2007;57(2):347–54. doi: 10.1016/j.jaad.2007.02.007.
  7. Armstrong A.W., Harskamp C.T., Armstrong E.J. The association between psoriasis and obesity: A systematic review and metaanalysis of observational studies. Nutr Diab. 2012;2:e54. doi: 10.1038/nutd.2012.26.
  8. Корсакова Ю.Л., Коротаева Т.В., Логинова Е.Ю. и др. Распространенность коморбидных и сопутствующих заболеваний при псориатическом артрите по данным общероссийского регистра больных псориатическим артритом. Научно-практическая ревматология. 2021;59(3):275–81. [Korsakova Yu.L., Korotaeva T.V., Loginova E.Yu. and others. Prevalence of comorbid and concomitant diseases in psoriatic arthritis according to the all-Russian register of patients with psoriatic arthritis. Scientific and practical rheumatology. 2021;59(3):275–81. (In Russ.)].
  9. Gonzalez-Parra E., Daudén E., Carrascosa J.M., et al. Kidney disease and psoriasis. a new comorbidity? Actas Dermosifiliogr. 2016;107(10):823–29. doi: 10.1016/j.adengl.2016.05.025.
  10. Ungprasert P., Raksasuk S. Psoriasis and risk of incident chronic kidney disease and end-stage renal disease: a systematic review and meta analysis. Int Urol. Nephrol. 2018;50(7):1277–83. doi: 10.1007/s11255-018-1868-z.
  11. Переверзина Н.О., Круглова Л.С., Коротаева Т.В., Лила А.М. Систематический обзор и мета-анализ: предикторы развития псориатического артрита. Фарматека. 2022;29(14):34–41. [Pereverzina N.O., Kruglova L.S., Korotaeva T.V., Lila A.M. Systematic review and meta-analysis: predictors of psoriatic arthritis. Farmateka. 2022;29(14):34–41. (In Russ.)]. doi: 10.18565/pharmateca.2022.14.34-41.
  12. Whitlock S.M., Enos C.W., Armstrong A.W., et al. Management of psoriasis in patients with inflammatory bowel disease: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 2018;78(2):383–94. doi: 10.1016/j.jaad.2017.06.043.
  13. Круглова Л.С., Бакулев А.Л., Коротаева Т.В. и др. Псориаз. М., 2022. [Kruglova L.S., Bakulev A.L., Korotaeva T.V. and others. Psoriasis. M., 2022. (In Russ.)].
  14. Tonel G., Conrad C., Laggner U., et al. Cutting edge: A critical functional role for IL-23 in psoriasis. J Immunol. 2010;185(10):5688–91. doi: 10.4049/jimmunol.1001538.
  15. Chi C.C., Wang J., Chen Y.F., et al. Risk of incident chronic kidney disease and end-stage renal disease in patients with psoriasis: A nationwide population-based cohort study. J Dermatol Sci. 2015;78(3):232–38. doi: 10.1016/j.jdermsci.2015.03.012.
  16. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346(16):1221–31. doi: 10.1056/NEJMra011775.
  17. Wenk K.S., Arrington K.C., Ehrlich A. Psoriasis and non-alcoholic fatty liver disease. J Eur Acad Dermatol Venereol. 2011;25(4):383–91. doi: 10.1111/j.1468-3083.2010.03841.x.
  18. Потекаев Н.Н., Жукова О.В., Артемье-ва С.И. Псориаз: персонифицированный подход к терапии. Предпочтительный выбор системных агентов с учетом коморбидных патологий. Медицинский совет. 2020;(12):28–34. [Potekaev N.N., Zhukova O.V., Artemyeva S.I. Psoriasis: a personalized approach to therapy. Preferred choice of systemic agents taking into account comorbid pathologies. Medical advice. 2020;(12):28–34. (In Russ.)]. doi: 10.21518/2079-701X-202012-28-34.

补充文件

附件文件
动作
1. JATS XML
下载
2. Рис. 1. Пациент с ПС кожи и множественными коморбидными патологиями

下载 (423KB)
索引源数据
3. Рис. 2. Число пациентов с достижением конечной точки PAS| 75, PAS| 90, PAS| 100 на фоне применения нетакимаба, %

下载 (93KB)
索引源数据
4. Рис. 3. Число пациентов с достижением конечной точки ДИКЖ<5 на фоне применения нетакимаба

下载 (49KB)
索引源数据
5. Рис. 4. Динамика показателей индекса BASDAI (баллы) на фоне применения нетакимаба

下载 (55KB)
索引源数据
##common.cookie##